In a post hoc analysis, POTELIGEO demonstrated a longer TTNT vs vorinostat26

TTNT for patients in the MAVORIC trial

Findings from the post hoc analysis cannot be used to demonstrate differences between treatments and may not be applicable to all patients initiating POTELIGEO.

  • TTNT was defined as the time to the start of any significant therapy, excluding topical steroids or focal radiation26
  • POTELIGEO also demonstrated longer TTNT vs vorinostat across blood classifications25
TTNT=time to next treatment REFERENCES +